GRI Bio, Inc. — Director's Dealing 2023

Apr 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GRI BIO, Inc. (GRI)
CIK: 0001824293
Period of Report: 2023-04-21

Reporting Person: Hertz Walter Marc (Director, Chief Executive Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-21	Common Stock	A	385510	—	Acquired	385510	Direct

Footnotes

F1: Received in exchange for 10,307,793 shares of common stock of GRI Bio, Inc. ("GRI"), pursuant to the Agreement and Plan of Merger, dated December 13, 2022, by and among Vallon Pharmaceuticals, Inc. (the "Company"), Vallon Merger Sub, Inc. and GRI Bio, Inc. (the "Merger"). Per the terms of the Merger, each share of GRI common stock was converted into the right to receive 0.0374 shares of the Company's common stock. In connection with the Merger, the Company effected a reverse stock split of the Company's common stock at a ratio of 1-for-30 (the "Reverse Split"). Unless noted otherwise, all references to share amounts in this Form 4 reflect the Reverse Split.